PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Contrast-enhanced ultrasound diagnosis of hepatic metastasis of concurrent medullary-papillary thyroid carcinoma: A case report.

Abstract Co-occurrence of medullary thyroid carcinoma (MTC) and papillary thyroid carcinoma (PTC) in the same thyroid gland with liver metastasis is a rare condition. To our knowledge, the utility of contrast-enhanced ultrasound (CEUS) to diagnose it is much less.
PMID
Related Publications

Contrast-enhanced ultrasound (CEUS) in hepatic lymphoma: retrospective evaluation in 38 cases.

Smoldering medullary thyroid carcinoma liver metastasis 37 years after resection of an organ-confined tumor.

Robot-assisted Sistrunk's operation, total thyroidectomy, and neck dissection via a transaxillary and retroauricular (TARA) approach in papillary carcinoma arising in thyroglossal duct cyst and thyroid gland.

Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.

Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules.

Authors

Mayor MeshTerms
Keywords
Journal Title medicine
Publication Year Start




PMID- 29390301
OWN - NLM
STAT- MEDLINE
DCOM- 20180212
LR  - 20180212
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 50
DP  - 2017 Dec
TI  - Contrast-enhanced ultrasound diagnosis of hepatic metastasis of concurrent
      medullary-papillary thyroid carcinoma: A case report.
PG  - e9065
LID - 10.1097/MD.0000000000009065 [doi]
AB  - RATIONALE: Co-occurrence of medullary thyroid carcinoma (MTC) and papillary
      thyroid carcinoma (PTC) in the same thyroid gland with liver metastasis is a rare
      condition. To our knowledge, the utility of contrast-enhanced ultrasound (CEUS)
      to diagnose it is much less. PATIENT CONCERNS: A 33-year-old female was referred 
      to our hospital due to the increase in plasma calcitonin concentration and
      carcino-embryonic antigen 12 months after her total thyroidectomy. To find
      metastasis, she received laboratory tests, gray-scale US, and CEUS. In our paper,
      ethical approval was not necessary, as this article is a case report, which is
      based on the clinical information of the patient. Because our case does not refer
      to the patient's privacy, informed consent is not necessary. DIAGNOSES:
      Gray-scale abdominal ultrasound image demonstrated a mildly hyperechoic nodule in
      the liver. In CEUS, the nodules were hyperenhanced in the arterial phase. In the 
      late arterial phase, the enhancement was washed out quickly. The nodules
      presented hypoenhancement in the portal and parenchymal phase, which conformed to
      the hepatic metastasis. INTERVENTIONS: The patient received thyroid and liver
      surgery. OUTCOMES: She was free of disease for 10 months at the time of this
      report. LESSONS: In this case, liver metastases from MTC can be detected and
      characterized reliably as hypoenhancing lesions during the portal venous and late
      phases of CEUS, washing out starts early, and is marked. We suspect MTC is a kind
      of tumor that tends to have rich blood supply and consider contrast-enhanced
      ultrasound as a suitable method for the follow-up of patients with MTC.
CI  - Copyright (c) 2017 The Authors. Published by Wolters Kluwer Health, Inc. All
      rights reserved.
FAU - Zhou, Jie
AU  - Zhou J
AD  - Department of Ultrasound.
FAU - Luo, Yan
AU  - Luo Y
AD  - Department of Ultrasound.
FAU - Ma, Bu Yun
AU  - Ma BY
AD  - Department of Ultrasound.
FAU - Ling, Wen Wu
AU  - Ling WW
AD  - Department of Ultrasound.
FAU - Zhu, Xiang Lan
AU  - Zhu XL
AD  - Department of Pathology, The West China Hospital of Sichuan University, Chengdu, 
      China.
LA  - eng
PT  - Case Reports
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Contrast Media)
RN  - 0 (Phospholipids)
RN  - 0 (contrast agent BR1)
RN  - WS7LR3I1D6 (Sulfur Hexafluoride)
RN  - Thyroid cancer, medullary
RN  - Thyroid cancer, papillary
SB  - AIM
SB  - IM
MH  - Adult
MH  - Carcinoma, Neuroendocrine/*pathology/surgery
MH  - Carcinoma, Papillary/*pathology/surgery
MH  - Contrast Media
MH  - Diagnosis, Differential
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/*diagnostic imaging/*secondary/surgery
MH  - Phospholipids
MH  - Sulfur Hexafluoride
MH  - Thyroid Neoplasms/*pathology/surgery
MH  - Thyroidectomy
MH  - Ultrasonography/*methods
EDAT- 2018/02/03 06:00
MHDA- 2018/02/13 06:00
CRDT- 2018/02/03 06:00
PHST- 2018/02/03 06:00 [entrez]
PHST- 2018/02/03 06:00 [pubmed]
PHST- 2018/02/13 06:00 [medline]
AID - 10.1097/MD.0000000000009065 [doi]
AID - 00005792-201712150-00051 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Dec;96(50):e9065. doi: 10.1097/MD.0000000000009065.